Bristol-Myers Squibb (NYSE:BMY) unit Celgene (NASDAQ:CELG) has withdrawn its marketing application in Europe for Idhifa (enasidenib) for the treatment of adults with acute myeloid leukemia (AML).
The company took action after determining that it
could not fully address EMA objections. Specifically, the agency
concluded that the data supporting the application were insufficient to
prove efficacy.
https://seekingalpha.com/news/3536875-celgene-withdraws-enasidenib-application-in-europe
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.